Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin

Pavan, Maria Helena Postal; Velho, Paulo Eduardo Neves Ferreira; Vigani, Aline Gonzalez; Gonçalves, Fernando L.; Aoki, Francisco Hideo

doi:10.1590/s1413-86702007000300017

Cited by 9 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By assessing RBV physiological levels in mono-infected and HIV coinfected patients, one study correlated lower response rates of HIV-infected patients with lower RBV bioavailability [21]. Interestingly, this combined therapy was surprisingly effective against disseminated human papillomavirus infection in a patient having previously undergone treatment for psoriasis [22], in HIV-HCV coinfected patients [23], as well as in a patient with acquired aplastic anemia [24].…”

Section: Ribavirin and Its Clinical Usementioning

confidence: 99%

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

Beaucourt

Vignuzzi

2014

Current Opinion in Virology

102

View full text Add to dashboard Cite

Ribavirin has proven to be effective against several viruses in the clinical setting and a multitude of viruses in vitro. With up to five different proposed mechanisms of action, recent advances have begun to discern the hierarchy of antiviral effects at play depending on the virus and the host conditions under scrutiny. Studies reveal that for many viruses, antiviral mechanisms may differ depending on cell type in vitro and in vivo. Further analyses are thus required to accurately identify mechanisms to more optimally determine clinical treatments. In recent years, a growing number of ribavirin resistant and sensitive variants have been identified. These variants not only inform on the specific mechanisms by which ribavirin enfeebles the virus, but also can themselves be tools to identify new antiviral compounds.

show abstract

Section: Ribavirin and Its Clinical Usementioning

confidence: 99%

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

Beaucourt

Vignuzzi

2014

Current Opinion in Virology

102

View full text Add to dashboard Cite

show abstract

“…Additionally, IFN and RBV may be used in combination for the treatment of special cases of human papillomavirus infection. 35–37 Thus, the findings of this study may have clinical implications for other areas of medical care.…”

Section: Introductionmentioning

confidence: 75%

Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation

Weiss

Prieto

Bräu

et al. 2018

Int J Psychiatry Med

View full text Add to dashboard Cite

Objective The primary study objective is to determine which measures of depression are associated with early discontinuation of hepatitis C virus infection treatment and to determine which measure best characterizes the depression that develops during treatment. Methods Seventy-eight treatment-naïve subjects who initiated pegylated interferon/ribavirin treatment for hepatitis C virus infection were included. Baseline depression was assessed with the Structured Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), the Hamilton Depression Rating Scale, and the Beck Depression Inventory-II. The latter two measures were repeated at treatment weeks 12 and 24. Results Depression scores, as measured by the three instruments, lacked adequate consistency. Baseline depression as measured by the Beck Depression Inventory-II, but not by the other scales, was associated with early treatment discontinuation at weeks 12 and 24. Changes in depression during treatment were restricted to somatic symptoms. Of those who completed treatment, those who were not depressed at baseline tended to demonstrate significant depression increases during treatment. Conclusion The Beck Depression Inventory-II is recommended to assess depression prior to hepatitis C virus infection treatment. Somatic symptoms of depression should be monitored during treatment. Baseline depression as measured by the Beck Depression Inventory-II was associated with early treatment discontinuation. The Beck Depression Inventory-II, Structured Interview for DSM-IV, and Hamilton Depression Rating Scale yielded results that were not consistent with each other in this sample. Future research should focus on standardizing depression assessment in medically ill populations to identify measures that predict treatment discontinuation.

show abstract

“…Although IFN is no longer used to treat HCV, IFN remains today a treatment option for multiple sclerosis and various cancers including leukemia and melanoma (Calabresi et al 2014; Mohr et al 2015; Bohn et al 2016). Additionally, IFN and RBV may be used in combination for the treatment of special cases of human papillomavirus (HPV) infection (Pavan et al 2007; Shrestha and Hamrock 2010; Mosa et al 2014). Thus, the findings of this study may have clinical implications for the treatment of other diseases.…”

Section: Treatment Of Hcv With Interferon and Ribavirinmentioning

confidence: 99%

Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin

et al. 2016

View full text Add to dashboard Cite

The Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. The goal of this research was to prospectively evaluate neurocognitive functioning among a group of HCV mono-infected and HIV/HCV-co-infected patients during the first 24 weeks of IFN/RBV treatment while accounting for practice effects, normal variations in change over time, and variations in IFN/RBV treatment exposure. Forty-four HCV mono-infected and 30 HIV/HCV co-infected patients were enrolled in a prospective study of patients beginning on IFN/RBV for chronic HCV infection. Patients were administered a depression inventory, a measure of fatigue, a structured psychiatric interview, and a neurocognitive battery at baseline and 24 weeks after initiation of treatment. Analyses were conducted to explore possible associations between neurocognitive functioning and the following: HIV/HCV co-infection versus HCV mono-infection, INF and RBV treatment exposure, psychiatric status, liver disease stage, and other medical characteristics. At baseline there were no significant differences between the two groups’ neuropsychiatric or neurocognitive function other than the mono-infected group had significantly higher reports of fatigue (p = 0.033). Over the course of 24 weeks of treatment after controlling for practice effects, the HIV/HCV co-infected patients experienced significantly greater declines in memory (t(56) = 2.14, p = 0.037) and global neurocognitive functioning (t(53) = 2.28, p = 0.027). In a well-characterized sample of mono- and co-infected patients, it appears that persons with HCV/HIV co-infection are potentially more vulnerable to neurocognitive sequalae during HCV treatment.

show abstract

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin

Abstract: We reported one case of human immunodeficiency virus and hepatitis C virus co-infected patient who presented a significant improvement of human papillomavirus (HPV) lesions during the treatment of chronic hepatitis using peg-interferon alfa-2b and ribavirin.

Cited by 9 publications

References 2 publications

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation

Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin

Contact Info

Product

Resources

About